प्रेडनिसोलोन के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें प्रेडनिसोलोन (Orapred, Millipred, Pediapred; कॉर्टिकोस्टेरॉइड) के 400 इंटरैक्शन दर्ज हैं: 29 गंभीर, 288 मध्यम, 82 मामूली, और 1 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (29)

  • आरफॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (आरफॉर्मोटेरोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • आर्सेनिक ट्राइऑक्साइडQT अंतराल बढ़ाने वाली दवागंभीर

    If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (आर्सेनिक ट्राइऑक्साइड लेबल, बॉक्स्ड चेतावनी)

  • इन्फ्लिक्सिमैबइम्यूनोसप्रेसेंटगंभीर

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (इन्फ्लिक्सिमैब लेबल, बॉक्स्ड चेतावनी)

  • उपाडासिटिनिबइम्यूनोसप्रेसेंटगंभीर

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (उपाडासिटिनिब लेबल, बॉक्स्ड चेतावनी)

  • Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (एक्सिटिनिब लेबल, चेतावनियां और सावधानियां)

  • एटाज़ानाविरएंटीरेट्रोवायरलगंभीर

    Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

  • एटैनरसेप्टइम्यूनोसप्रेसेंटगंभीर

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (एटैनरसेप्ट लेबल, बॉक्स्ड चेतावनी)

  • एडालिमुमैबइम्यूनोसप्रेसेंटगंभीर

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (एडालिमुमैब लेबल, बॉक्स्ड चेतावनी)

  • एड्रेनालिनसिम्पैथोमिमेटिकगंभीर

    …Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

  • एबिराटेरोनCYP2D6 इनहिबिटरगंभीर

    At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (एबिराटेरोन लेबल, चेतावनियां और सावधानियां)

  • …(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • कीटोकोनाज़ोलएज़ोल एंटीफंगलगंभीर

    Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • टोफासिटिनिबइम्यूनोसप्रेसेंटगंभीर

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोफासिटिनिब लेबल, बॉक्स्ड चेतावनी)

  • टोसिलिज़ुमैबइम्यूनोसप्रेसेंटगंभीर

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

  • ट्रेटिनोइनरेटिनॉइडगंभीर

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (ट्रेटिनोइन लेबल, बॉक्स्ड चेतावनी)

  • ट्रैंडोलाप्रिलACE इनहिबिटरगंभीर

    Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (ट्रैंडोलाप्रिल लेबल, चेतावनियां)

  • Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

  • फॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (फॉर्मोटेरोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फोसएम्प्रेनाविरएंटीरेट्रोवायरलगंभीर

    Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (फोसएम्प्रेनाविर लेबल, दवाओं के इंटरैक्शन)

  • बैरिसिटिनिबJAK इनहिबिटरगंभीर

    Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (बैरिसिटिनिब लेबल, बॉक्स्ड चेतावनी)

  • माइटोटेनCYP3A4 इंड्यूसरगंभीर

    If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

  • मिफेप्रिस्टोनCYP3A4 इनहिबिटरगंभीर

    WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (मिफेप्रिस्टोन लेबल, बॉक्स्ड चेतावनी)

  • मोएक्सिप्रिलACE इनहिबिटरगंभीर

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (मोएक्सिप्रिल लेबल, चेतावनियां)

  • यूमेक्लिडिनियम और विलैंटेरोलएंटीकोलिनर्जिकगंभीर

    • use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (यूमेक्लिडिनियम और विलैंटेरोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • रिल्पिविरिनएंटीरेट्रोवायरलगंभीर

    Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (रिल्पिविरिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • लोवास्टेटिनस्टेटिनगंभीर

    Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (लोवास्टेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सिरोलिमसइम्यूनोसप्रेसेंटगंभीर

    In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (सिरोलिमस लेबल, चेतावनियां और सावधानियां)

  • सैल्मेटेरोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (सैल्मेटेरोल लेबल, बॉक्स्ड चेतावनी)

  • Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (सोमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

मध्यम इंटरैक्शन (288)

  • Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (अफाटिनिब लेबल, चेतावनियां और सावधानियां)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (आइवरमेक्टिन लेबल, चेतावनियां)

  • आइवाकैफ्टरCYP3A4 इनहिबिटरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • आइसोनियाज़िडएंटीबायोटिकमध्यम

    Antitubercular drugs: Serum concentrations of isoniazid may be decreased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • आर्गाट्रोबैनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • आर्मोडाफिनिलCNS स्टिमुलेंटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन एस्पार्टइंसुलिनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन ग्लार्जिनइंसुलिनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन डेग्लुडेकइंसुलिनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन डेटेमिरइंसुलिनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन लिस्प्रोइंसुलिनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इट्राकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इबैंड्रोनेटबिस्फॉस्फोनेटमध्यम

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (इबैंड्रोनेट लेबल, चेतावनियां और सावधानियां)

  • इमैटिनिबCYP3A4 इनहिबिटरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एकार्बोज़एंटीडायबिटिक (डायबिटीज़ की दवा)मध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एक्लिडिनियमएंटीकोलिनर्जिकमध्यम

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (एक्लिडिनियम लेबल, दवाओं के इंटरैक्शन)

  • एक्सेनाटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एज़िथ्रोमाइसिनमैक्रोलाइड एंटीबायोटिकमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एटोडोलैकNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एट्राविरिनएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एडोक्साबैनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एनोक्सापैरिनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एपिक्साबैनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एप्रेपिटेंटCYP3A4 इनहिबिटरमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एफाविरेंज़एंटीरेट्रोवायरलमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एफेड्रिनसिम्पैथोमिमेटिकमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एमियोडेरोनएंटीएरिदमिकमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एम्पाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एम्फोटेरिसिन Bएंटीफंगलमध्यम

    Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (एम्फोटेरिसिन B लेबल, दवाओं के इंटरैक्शन)

  • एरिथ्रोमाइसिनमैक्रोलाइड एंटीबायोटिकमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (एर्लोटिनिब लेबल, चेतावनियां और सावधानियां)

  • एलिस्किरेनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (एलिस्किरेन लेबल, चेतावनियां और सावधानियां)

  • एलेंड्रोनेटबिस्फॉस्फोनेटमध्यम

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (एलेंड्रोनेट लेबल, चेतावनियां और सावधानियां)

  • Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

  • एलेमटुज़ुमैबइम्यूनोसप्रेसेंटमध्यम

    Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (एलेमटुज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • एलोग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (एल्पेलिसिब लेबल, चेतावनियां और सावधानियां)

  • Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (एल्बेंडाज़ोल लेबल, चेतावनियां और सावधानियां)

  • CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एवरोलिमसइम्यूनोसप्रेसेंटमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एस्ट्राडियोलएस्ट्रोजनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एस्ट्राडियोल और डायनोजेस्टगर्भनिरोधक गोलीमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एस्पिरिनNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एस्पिरिन और डाइपिरिडामोलएंटीप्लेटलेट दवामध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एस्लिकार्बाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सकार्बाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सीकोडोनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीकोडोन लेबल, चेतावनियां और सावधानियां)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीकोडोन और पैरासिटामोल लेबल, चेतावनियां और सावधानियां)

  • ऑक्सीमॉर्फोनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ओक्रेलिज़ुमैबइम्यूनोसप्रेसेंटमध्यम

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (ओक्रेलिज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • ओफ्लॉक्सासिनफ्लुओरोक्विनोलोनमध्यम

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (ओफ्लॉक्सासिन लेबल, चेतावनियां)

  • Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (ओमालिज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • ओलिसेरिडिनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ओलिसेरिडिन लेबल, चेतावनियां और सावधानियां)

  • कंजुगेटेड एस्ट्रोजनएस्ट्रोजनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • कार्बामाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • कीटोरोलैकNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • कैनाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • कोकेनलोकल एनेस्थेटिकमध्यम

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (कोकेन लेबल, दवाओं के इंटरैक्शन)

  • कोडीनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (कोडीन लेबल, चेतावनियां और सावधानियां)

  • कोलेस्टिरामिनबाइल एसिड सीक्वेस्ट्रेंटमध्यम

    Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • क्लैड्रिबिनएंटीमेटाबोलाइटमध्यम

    Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (क्लैड्रिबिन लेबल, दवाओं के इंटरैक्शन)

  • क्लैरिथ्रोमाइसिनमैक्रोलाइड एंटीबायोटिकमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • क्लोबाज़ामबेंज़ोडायज़ेपिनमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्रिसियोफुल्विनएंटीफंगलमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लिपिज़ाइडसल्फोनिलयूरियामध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लिपिज़ाइड और मेटफॉर्मिनसल्फोनिलयूरियामध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लिबेनक्लामाइडसल्फोनिलयूरियामध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लिबेनक्लामाइड और मेटफॉर्मिनसल्फोनिलयूरियामध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लिमेपिराइडसल्फोनिलयूरियामध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (ग्लिसरॉल फिनाइलब्यूटिरेट लेबल, दवाओं के इंटरैक्शन)

  • Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (ज़ेनोक्यूटुज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • ज़ोलेड्रोनिक एसिडबिस्फॉस्फोनेटमध्यम

    A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (ज़ोलेड्रोनिक एसिड लेबल, चेतावनियां और सावधानियां)

  • टरब्यूटालिनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (टरब्यूटालिन लेबल, चेतावनियां)

  • टिकाग्रेलोरएंटीप्लेटलेट दवामध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • टियोट्रोपियमएंटीकोलिनर्जिकमध्यम

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

  • टिर्ज़ेपाटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • टेपेंटाडोलओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (टेपेंटाडोल लेबल, चेतावनियां और सावधानियां)

  • Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

  • If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

  • टेरिपैराटाइडथायरॉइड हार्मोनमध्यम

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (टेसामोरेलिन लेबल, दवाओं के इंटरैक्शन)

  • टेस्टोस्टेरोनएंड्रोजनमध्यम

    Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

  • टॉरसेमाइडलूप डाइयूरेटिकमध्यम

    Corticosteroids and ACTH: Increased risk of hypokalemia. (टॉरसेमाइड लेबल, दवाओं के इंटरैक्शन)

  • टोपिरामेटएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • टोल्मेटिनNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ट्रामाडोलओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ट्रामाडोल लेबल, चेतावनियां और सावधानियां)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ट्रामाडोल और पैरासिटामोल लेबल, चेतावनियां और सावधानियां)

  • ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

  • Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (ट्रैस्टुज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डाइसाइक्लोमिनएंटीकोलिनर्जिकमध्यम

    Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

  • डारुनाविरएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डारुनाविर और कोबिसिस्टैटएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डिगॉक्सिनडिजिटेलिस ग्लाइकोसाइडमध्यम

    Digitalis: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डिल्टियाज़ेमकैल्शियम चैनल ब्लॉकरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (डुपिलुमैब लेबल, चेतावनियां और सावधानियां)

  • डुलाग्लूटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्सामेथासोनकॉर्टिकोस्टेरॉइडमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (डेनोसुमैब लेबल, चेतावनियां और सावधानियां)

  • डेफेरासिरोक्सआयरन सप्लीमेंटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डैपाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डैप्टोमाइसिनएंटीबायोटिकमध्यम

    Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (डैप्टोमाइसिन लेबल, चेतावनियां और सावधानियां)

  • डैबिगैट्रानएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ड्रोनेडेरोनएंटीएरिदमिकमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • थियोफाइलिनमिथाइलज़ैंथिनमध्यम

    Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (थियोफाइलिन लेबल, चेतावनियां)

  • नालबुफिनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (नालबुफिन लेबल, चेतावनियां)

  • नाल्ट्रेक्सोन और ब्यूप्रोपियॉनओपिओइड एंटागोनिस्टमध्यम

    …hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

  • Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (निंटेडानिब लेबल, चेतावनियां और सावधानियां)

  • CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • नेटेग्लिनाइडमेग्लिटिनाइडमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • नेफाज़ोडोनएंटीडिप्रेसेंटमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • नेविरापिनएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • नैटालिज़ुमैबइम्यूनोसप्रेसेंटमध्यम

    In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (नैटालिज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • नैफसिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • नैबुमेटोनNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • नॉरएथिस्टेरोनप्रोजेस्टिनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पाल्बोसिक्लिबCYP3A4 इनहिबिटरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पियोग्लिटाज़ोनथायज़ोलिडिनडायोनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पियोग्लिटाज़ोन और ग्लिमेपिराइडथायज़ोलिडिनडायोनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पियोग्लिटाज़ोन और मेटफॉर्मिनथायज़ोलिडिनडायोनमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (पेंटाज़ोसिन और नालोक्सोन लेबल, चेतावनियां)

  • पेथिडीनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (पेथिडीन लेबल, चेतावनियां और सावधानियां)

  • Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (पेनिसिलामिन लेबल, चेतावनियां)

  • पेरैम्पेनलएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पैमिड्रोनेटबिस्फॉस्फोनेटमध्यम

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (पैमिड्रोनेट लेबल, चेतावनियां और सावधानियां)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (पैरासिटामोल और कोडीन लेबल, चेतावनियां)

  • If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (पैसिरियोटाइड लेबल, चेतावनियां और सावधानियां)

  • पोनेसिमोडइम्यूनोसप्रेसेंटमध्यम

    Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (पोनेसिमोड लेबल, चेतावनियां और सावधानियां)

  • पोसाकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • प्रिमिडोनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • प्रेडनिसोनकॉर्टिकोस्टेरॉइडमध्यम

    Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (प्रेडनिसोन लेबल, चेतावनियां और सावधानियां)

  • प्रोजेस्टेरोनप्रोजेस्टिनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • प्रोपाइलथायोयूरेसिलएंटीथायरॉइड दवामध्यम

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • प्रोपोफोलCNS डिप्रेसेंटमध्यम

    The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (प्रोपोफोल लेबल, चेतावनियां और सावधानियां)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (प्रोमेथाज़िन और कोडीन लेबल, चेतावनियां और सावधानियां)

  • फिंगोलिमोडइम्यूनोसप्रेसेंटमध्यम

    In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (फिंगोलिमोड लेबल, चेतावनियां और सावधानियां)

  • फिडैक्सोमाइसिनमैक्रोलाइड एंटीबायोटिकमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फिनाइलएफ्रिनडीकंजेस्टेंटमध्यम

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

  • फुल्वेस्ट्रेंटएस्ट्रोजनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फेंटरमिन और टोपिरामेटCNS स्टिमुलेंटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फेंटानिलओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (फेंटानिल लेबल, चेतावनियां और सावधानियां)

  • फेनिटोइनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फेनोबार्बिटोनबार्बिट्यूरेटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फॉस्फेनिटोइनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फोंडापैरिनक्सएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फोसाप्रेपिटेंटCYP3A4 इनहिबिटरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फ्लुओसिनोनाइडकॉर्टिकोस्टेरॉइडमध्यम

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (फ्लुओसिनोनाइड लेबल, चेतावनियां और सावधानियां)

  • फ्लुकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फ्लुटिकासोन और सैल्मेटेरोलकॉर्टिकोस्टेरॉइडमध्यम

    In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, चेतावनियां और सावधानियां)

  • फ्लुनिसोलाइडकॉर्टिकोस्टेरॉइडमध्यम

    Pregnancy As with other corticosteroids, flunisolide has been shown to be teratogenic and fetotoxic in rabbits and rats at oral doses of 40 and 200 mcg/kg/day, respectively (approximately 2 and 4 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m 2 basis). (फ्लुनिसोलाइड लेबल, सावधानियां)

  • बाल्सालाज़ाइडसैलिसिलेटमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

  • बिवालिरुडिनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • बिस्मथ सबसैलिसिलेटसैलिसिलेटमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • बुडेसोनाइड और फॉर्मोटेरोलकॉर्टिकोस्टेरॉइडमध्यम

    In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, चेतावनियां और सावधानियां)

  • Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (बेंडामुस्टिन लेबल, चेतावनियां और सावधानियां)

  • बेक्लोमेथासोनकॉर्टिकोस्टेरॉइडमध्यम

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (बेक्लोमेथासोन लेबल, चेतावनियां और सावधानियां)

  • बेक्साग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (बेनरालिज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • बेलाडोना और ओपियमओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (बेलाडोना और ओपियम लेबल, चेतावनियां और सावधानियां)

  • बोसेंटनCYP3A4 इंड्यूसरमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूटाल्बिटल और पैरासिटामोलबार्बिट्यूरेटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूटॉर्फेनॉलओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ब्यूटॉर्फेनॉल लेबल, चेतावनियां)

  • ब्यूप्रेनॉर्फिनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ब्यूप्रेनॉर्फिन लेबल, चेतावनियां और सावधानियां)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, चेतावनियां और सावधानियां)

  • ब्यूप्रोपियॉनएंटीडिप्रेसेंटमध्यम

    …risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

  • माइकाफंगिनएंटीफंगलमध्यम

    Effect of Micafungin in Sodium Chloride Injection on Other Drugs CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. (माइकाफंगिन लेबल, दवाओं के इंटरैक्शन)

  • In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (मार्गेटुक्सिमैब लेबल, चेतावनियां और सावधानियां)

  • मिग्लिटोलएंटीडायबिटिक (डायबिटीज़ की दवा)मध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मिटापिवैटCYP3A4 इंड्यूसरमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मिथाइलटेस्टोस्टेरोनएंड्रोजनमध्यम

    Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (मिथाइलटेस्टोस्टेरोन लेबल, चेतावनियां)

  • मिथाइलडोपाएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    If not, corticosteroids may be given and other causes of anemia should be considered. (मिथाइलडोपा लेबल, चेतावनियां)

  • मिराबेग्रॉनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मेजेस्ट्रोलप्रोजेस्टिनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मेटफॉर्मिनबाइगुआनाइडमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • This can be corrected by giving appropriate doses of corticosteroids. (मेटाइरापोन लेबल, चेतावनियां और सावधानियां)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकमध्यम

    Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (मेटोलाज़ोन लेबल, दवाओं के इंटरैक्शन)

  • मेड्रोक्सीप्रोजेस्टेरोनप्रोजेस्टिनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मेथाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरमध्यम

    Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (मेथाज़ोलामाइड लेबल, दवाओं के इंटरैक्शन)

  • मेथाडोनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (मेथाडोन लेबल, चेतावनियां और सावधानियां)

  • मेथिमाज़ोलएंटीथायरॉइड दवामध्यम

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • मेथोट्रेक्सेटइम्यूनोसप्रेसेंटमध्यम

    NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (मेथोट्रेक्सेट लेबल, दवाओं के इंटरैक्शन)

  • मेथोहेक्सिटलबार्बिट्यूरेटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Decrease corticosteroids gradually, if appropriate. (मेपोलिज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मेसालामाइनसैलिसिलेटमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मॉक्सीफ्लॉक्सासिनफ्लुओरोक्विनोलोनमध्यम

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

  • मॉर्फिनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (मॉर्फिन लेबल, चेतावनियां और सावधानियां)

  • मोंटेलुकास्टल्यूकोट्राइन रिसेप्टर एंटागोनिस्टमध्यम

    Inhaled corticosteroid may be reduced gradually. (मोंटेलुकास्ट लेबल, चेतावनियां और सावधानियां)

  • मोडाफिनिलCNS स्टिमुलेंटमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मोमेटासोनकॉर्टिकोस्टेरॉइडमध्यम

    Lung function (FEV 1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (मोमेटासोन लेबल, चेतावनियां और सावधानियां)

  • रिटोनाविरएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रिफापेंटिनएंटीबायोटिकमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रिफाब्यूटिनएंटीबायोटिकमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रिफैम्पिसिनएंटीबायोटिकमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रिवारोक्साबैनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रिसेड्रोनेटबिस्फॉस्फोनेटमध्यम

    …the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (रिसेड्रोनेट लेबल, चेतावनियां और सावधानियां)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रेपाग्लिनाइडमेग्लिटिनाइडमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रैनोलाज़िनQT अंतराल बढ़ाने वाली दवामध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रोक्यूरोनियमन्यूरोमस्कुलर ब्लॉकरमध्यम

    Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

  • लिनाग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • लियोथायरोनिनथायरॉइड हार्मोनमध्यम

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • लिराग्लूटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (लिसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

  • लेनाकैपाविरएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • लेवॉर्फेनॉलओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (लेवॉर्फेनॉल लेबल, चेतावनियां)

  • लेवोथायरोक्सिनथायरॉइड हार्मोनमध्यम

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • लेवोथायरोक्सिन और लियोथायरोनिनथायरॉइड हार्मोनमध्यम

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • लेवोनॉरजेस्ट्रेलप्रोजेस्टिनमध्यम

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • लेवोफ्लॉक्सासिनफ्लुओरोक्विनोलोनमध्यम

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (लेवोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

  • लेवोसैल्बुटामोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (लेवोसैल्बुटामोल लेबल, चेतावनियां और सावधानियां)

  • लोपिनाविर और रिटोनाविरएंटीरेट्रोवायरलमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • लोरलाटिनिबCYP3A4 इंड्यूसरमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • वारफेरिनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • वेरापामिलकैल्शियम चैनल ब्लॉकरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • वैल्प्रोइक एसिडएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (वैल्प्रोइक एसिड लेबल, दवाओं के इंटरैक्शन)

  • वोरिकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सक्सिनिलकोलिनन्यूरोमस्कुलर ब्लॉकरमध्यम

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (सक्सिनिलकोलिन लेबल, दवाओं के इंटरैक्शन)

  • सल्फासालाज़िनसल्फोनामाइडमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोस्पोरिनइम्यूनोसप्रेसेंटमध्यम

    Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • साइटाराबिनएंटीमेटाबोलाइटमध्यम

    These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (साइटाराबिन लेबल, चेतावनियां)

  • साल्सालेटNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सिटाग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सिप्रोफ्लॉक्सासिनफ्लुओरोक्विनोलोनमध्यम

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (सिप्रोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

  • सिमेटिडीनH2 ब्लॉकरमध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सुज़ेट्रिजिनCYP3A4 इंड्यूसरमध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सुलिंडैकNSAIDमध्यम

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सुवोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)मध्यम

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सेनोबामेटएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सेफॉक्सिटिनसेफालोस्पोरिनमध्यम

    High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (सेफॉक्सिटिन लेबल, चेतावनियां और सावधानियां)

  • सेमाग्लूटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सैक्साग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • सैल्बुटामोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (सैल्बुटामोल लेबल, चेतावनियां और सावधानियां)

  • Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (सोडियम फिनाइलएसीटेट और सोडियम बेंज़ोएट लेबल, दवाओं के इंटरैक्शन)

  • Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (सोडियम फिनाइलब्यूटिरेट लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रालाज़िनवैसोडाइलेटरमध्यम

    Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (हाइड्रालाज़िन लेबल, चेतावनियां)

  • हाइड्रोकोडोनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन लेबल, चेतावनियां और सावधानियां)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, चेतावनियां और सावधानियां)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, चेतावनियां और सावधानियां)

  • हाइड्रोमॉर्फोनओपिओइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • हेपरिनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • हेलोपेरिडोलएंटीसाइकोटिकमध्यम

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (हेलोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

  • हेलोबेटासोलकॉर्टिकोस्टेरॉइडमध्यम

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (हेलोबेटासोल लेबल, चेतावनियां और सावधानियां)

मामूली ज़िक्र (82)

  • इंडापामाइडथायज़ाइड डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • इप्राट्रोपियमएंटीकोलिनर्जिकमामूली

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (इप्राट्रोपियम लेबल, दवाओं के इंटरैक्शन)

  • इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • उस्टेकिनुमैबइम्यूनोसप्रेसेंटमामूली

    Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (उस्टेकिनुमैब लेबल, चेतावनियां और सावधानियां)

  • एटेनोलोल और क्लोरथैलिडोनबीटा ब्लॉकरमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एप्लेरेनोनएल्डोस्टेरोन एंटागोनिस्टमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एमिकासिनएमिनोग्लाइकोसाइडमामूली

    Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (एमिकासिन लेबल, चेतावनियां और सावधानियां)

  • एमिलोराइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • एम्पीसिलिनपेनिसिलिन एंटीबायोटिकमामूली

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (एम्पीसिलिन लेबल, चेतावनियां)

  • एम्फेटामाइनCNS स्टिमुलेंटमामूली

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (एल्टेप्लेज़ लेबल, चेतावनियां और सावधानियां)

  • एसिटाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सासिलिनपेनिसिलिन एंटीबायोटिकमामूली

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (ऑक्सासिलिन लेबल, चेतावनियां)

  • ओलैंज़ापिन और फ्लुओक्सेटिनएंटीसाइकोटिकमामूली

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • कैनाबिडियोल (प्रिस्क्रिप्शन दवा)एंटीकन्वल्सेंट (दौरे की दवा)मामूली

    Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (कैनाबिडियोल (प्रिस्क्रिप्शन दवा) लेबल, चेतावनियां और सावधानियां)

  • कैल्सिट्रिओलविटामिन D एनालॉगमामूली

    Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (कैल्सिट्रिओल लेबल, दवाओं के इंटरैक्शन)

  • The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (कॉर्टिकोट्रोपिन लेबल, चेतावनियां और सावधानियां)

  • क्लोफाराबिनएंटीमेटाबोलाइटमामूली

    The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (क्लोफाराबिन लेबल, चेतावनियां और सावधानियां)

  • क्लोमीफीनसेलेक्टिव एस्ट्रोजन रिसेप्टर मॉड्यूलेटरमामूली

    Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (क्लोमीफीन लेबल, चेतावनियां)

  • क्लोरथैलिडोनथायज़ाइड डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • क्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • क्विनीनमलेरिया-रोधी दवामामूली

    Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (क्विनीन लेबल, दवाओं के इंटरैक्शन)

  • गुसेलकुमैबइम्यूनोसप्रेसेंटमामूली

    TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (गुसेलकुमैब लेबल, चेतावनियां और सावधानियां)

  • गैलेंटामिनकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लूकागॉनमामूली

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (ग्लूकागॉन लेबल, चेतावनियां और सावधानियां)

  • ज़िप्रासिडोनएंटीसाइकोटिकमामूली

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

  • If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (टेनेक्टेप्लेज़ लेबल, चेतावनियां और सावधानियां)

  • टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • टोब्रामाइसिनएमिनोग्लाइकोसाइडमामूली

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (टोब्रामाइसिन लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमटेरिनपोटैशियम-स्पेयरिंग डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • डासाटिनिबमामूली

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (डासाटिनिब लेबल, चेतावनियां और सावधानियां)

  • डेक्सट्रोएम्फेटामाइनCNS स्टिमुलेंटमामूली

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • डोनेपेज़िलकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • ड्रोपेरिडोलडोपामिन एंटागोनिस्टमामूली

    These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (ड्रोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

  • नाल्ट्रेक्सोनओपिओइड एंटागोनिस्टमामूली

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (नाल्ट्रेक्सोन लेबल, चेतावनियां और सावधानियां)

  • नियोस्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पाइरिडोस्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • पेनिसिलिन Gपेनिसिलिन एंटीबायोटिकमामूली

    Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (पेनिसिलिन G लेबल, चेतावनियां)

  • पेनिसिलिन Vपेनिसिलिन एंटीबायोटिकमामूली

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (पेनिसिलिन V लेबल, चेतावनियां)

  • फाइसोस्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • फ्लुडाराबिनएंटीमेटाबोलाइटमामूली

    Steroids may or may not be effective in controlling these hemolytic episodes. (फ्लुडाराबिन लेबल, चेतावनियां और सावधानियां)

  • फ्लुड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमामूली

    Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (प्रेडनिसोलोन लेबल, चेतावनियां और सावधानियां)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • बुमेटेनाइडलूप डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • बुसल्फानमामूली

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (बुसल्फान लेबल, चेतावनियां)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • बेम्पेडोइक एसिडOATP1B1 इनहिबिटरमामूली

    Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (बेम्पेडोइक एसिड लेबल, चेतावनियां और सावधानियां)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (बेवासिज़ुमैब लेबल, चेतावनियां और सावधानियां)

  • Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)

  • मिडोड्रिनअल्फा-एड्रीनर्जिक एगोनिस्टमामूली

    Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (मिडोड्रिन लेबल, दवाओं के इंटरैक्शन)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मेथएम्फेटामाइनCNS स्टिमुलेंटमामूली

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (मेथएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • मेमेंटिन और डोनेपेज़िलकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मेलफलानमामूली

    The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (मेलफलान लेबल, चेतावनियां)

  • रिटुक्सिमैबइम्यूनोसप्रेसेंटमामूली

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (रिटुक्सिमैब लेबल, चेतावनियां और सावधानियां)

  • रिवास्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • रैलोक्सीफेनसेलेक्टिव एस्ट्रोजन रिसेप्टर मॉड्यूलेटरमामूली

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (रैलोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (लेनालिडोमाइड लेबल, चेतावनियां और सावधानियां)

  • लोसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • विटामिन Dविटामिन और मिनरलमामूली

    प्रेडनिसोन जैसे कॉर्टिकोस्टेरॉइड कैल्शियम का अवशोषण कम करते हैं और विटामिन D के मेटाबॉलिज़्म को बिगाड़ते हैं, जिससे हड्डियों के क्षय में योगदान होता है। (NIH Office of Dietary Supplements, Vitamin D)

  • सेफडिनिरसेफालोस्पोरिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफडिनिर लेबल, चेतावनियां)

  • सेफप्रोज़िलसेफालोस्पोरिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफप्रोज़िल लेबल, चेतावनियां)

  • सेफाक्लोरसेफालोस्पोरिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • सेफाड्रोक्सिलसेफालोस्पोरिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाड्रोक्सिल लेबल, चेतावनियां और सावधानियां)

  • सेफोटेटनसेफालोस्पोरिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफोटेटन लेबल, चेतावनियां)

  • सेफ्टाज़िडिमसेफालोस्पोरिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • सेफ्ट्रिएक्सोनसेफालोस्पोरिनमामूली

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (सेफ्ट्रिएक्सोन लेबल, चेतावनियां और सावधानियां)

  • स्पिरोनोलैक्टोनएल्डोस्टेरोन एंटागोनिस्टमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइडएल्डोस्टेरोन एंटागोनिस्टमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमामूली

    Amphotericin B: There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see also Potassium depleting agents). (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रोक्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

कोई महत्वपूर्ण इंटरैक्शन नहीं बताया गया (1)

  • एमिनोफाइलिनमिथाइलज़ैंथिनकोई इंटरैक्शन नहीं

    …vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline tocainide… (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

आप जो कुछ भी लेते हैं, उस सबके साथ प्रेडनिसोलोन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।